[
    [
        {
            "time": "",
            "original_text": "9只创新高股获主力资金抢筹凯莱英净流入资金居首",
            "features": {
                "keywords": [
                    "创新高",
                    "主力资金",
                    "凯莱英",
                    "净流入"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "9只创新高股获主力资金抢筹凯莱英净流入资金居首",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "大跌82%，市值蒸发逾3400亿，科技龙头再创新低！大消费板块牛股频现，能否持续跑赢大盘？ 连续下跌",
            "features": {
                "keywords": [
                    "大跌",
                    "科技龙头",
                    "创新低",
                    "大消费",
                    "牛股",
                    "连续下跌"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技",
                    "消费"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "大跌82%，市值蒸发逾3400亿，科技龙头再创新低！大消费板块牛股频现，能否持续跑赢大盘？ 连续下跌",
                "Correlation": 5,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "凯莱英(002821)2021年一季报点评：剔除汇率和激励影响后业绩符合预期",
            "features": {
                "keywords": [
                    "凯莱英",
                    "一季报",
                    "业绩",
                    "符合预期",
                    "汇率",
                    "激励"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "凯莱英(002821)2021年一季报点评：剔除汇率和激励影响后业绩符合预期",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "高瓴资本概念股走势分化，健康元、凯莱英、海正药业、泰格医药强势上扬",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "概念股",
                    "走势分化",
                    "健康元",
                    "凯莱英",
                    "海正药业",
                    "泰格医药",
                    "强势上扬"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "高瓴资本概念股走势分化，健康元、凯莱英、海正药业、泰格医药强势上扬",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药行业2020年年报＆2021Q1季报小结及前瞻：业绩恢复强劲 高景气赛道表现亮眼",
            "features": {
                "keywords": [
                    "医药行业",
                    "年报",
                    "季报",
                    "业绩恢复",
                    "高景气赛道",
                    "表现亮眼"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业2020年年报＆2021Q1季报小结及前瞻：业绩恢复强劲 高景气赛道表现亮眼",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "中泰证券：国内CRO/CDMO行业全面恢复，把握具备长期成长性的板块优质公司",
            "features": {
                "keywords": [
                    "中泰证券",
                    "CRO/CDMO",
                    "全面恢复",
                    "长期成长性",
                    "优质公司"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "中泰证券：国内CRO/CDMO行业全面恢复，把握具备长期成长性的板块优质公司",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]